Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Mindy Sampson, DO
University of South Florida
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Infectious Disease Associates of Tampa Bay
Tampa, Florida, United States
- Tampa General Hospital
Tampa, Florida, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Sept 2019
- Primary completion
- 11 Jun 2022
- Completion
- 11 Jun 2022
- Last update posted
- 21 Apr 2023
- Registered enrollment
- 26
- Registry id
- NCT04000555
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.